Ionis Pharmaceuticals Inc. (IONS) has disclosed a new risk, in the Debt & Financing category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ionis Pharmaceuticals Inc. faces significant risks related to its securities and the global credit markets, particularly if it fails to progress in its programs as anticipated. The company’s share price is vulnerable to fluctuations based on the timing and achievement of various clinical, regulatory, and commercial milestones, which are often based on assumptions outside its control. Failure to meet these milestones or analysts’ forecasts could lead to a decrease in the market price of its common stock, affecting investor confidence. Additionally, the volatility of its securities could complicate liquidation efforts and increase the risk of financial loss for investors.
Overall, Wall Street has a Strong Buy consensus rating on IONS stock based on 17 Buys and 4 Holds.
To learn more about Ionis Pharmaceuticals Inc.’s risk factors, click here.